S McLean1, C McHale, H Enright. 1. Department of Haematology, Adelaide and Meath Hospital, Dublin, Incorporating the National Children's Hospital, Tallaght, D24, Dublin, Ireland. Smclean81@yahoo.com
Abstract
BACKGROUND: There is a paucity of data regarding hematological abnormalities in adults with Down's syndrome (DS). AIMS: We aimed to characterize hematological abnormalities in adult patients with DS and determine their long-term significance. METHODS: We retrospectively studied a cohort of nine DS patients referred to the adult hematology service in our institution between May 2001 and April 2008. Data collected were: full blood count (FBC), comorbidities, investigations performed, duration of follow-up and outcome to most recent follow-up. RESULTS: Median follow-up was 26 months (9-71). Of the nine patients, two had myelodysplastic syndrome (MDS) at presentation. Of these, one progressed, with increasing marrow failure, and requiring support with transfusions and gCSF. The remaining eight patients, with a variety of hematological abnormalities including leukopenia, macrocytosis, and thrombocytopenia, had persistently abnormal FBCs. However there was no evidence of progression, and no patient has evolved to acute myeloid leukemia (AML). CONCLUSIONS: MDS is a complication of DS and may require supportive therapy. However, minor hematological abnormalities are common in adult DS patients, and may not signify underlying marrow disease.
BACKGROUND: There is a paucity of data regarding hematological abnormalities in adults with Down's syndrome (DS). AIMS: We aimed to characterize hematological abnormalities in adult patients with DS and determine their long-term significance. METHODS: We retrospectively studied a cohort of nine DS patients referred to the adult hematology service in our institution between May 2001 and April 2008. Data collected were: full blood count (FBC), comorbidities, investigations performed, duration of follow-up and outcome to most recent follow-up. RESULTS: Median follow-up was 26 months (9-71). Of the nine patients, two had myelodysplastic syndrome (MDS) at presentation. Of these, one progressed, with increasing marrow failure, and requiring support with transfusions and gCSF. The remaining eight patients, with a variety of hematological abnormalities including leukopenia, macrocytosis, and thrombocytopenia, had persistently abnormal FBCs. However there was no evidence of progression, and no patient has evolved to acute myeloid leukemia (AML). CONCLUSIONS:MDS is a complication of DS and may require supportive therapy. However, minor hematological abnormalities are common in adult DS patients, and may not signify underlying marrow disease.
Authors: Yvette C M de Hingh; Petrus W van der Vossen; Eugenie F A Gemen; André B Mulder; Wim C J Hop; Frank Brus; Esther de Vries Journal: J Pediatr Date: 2005-12 Impact factor: 4.406
Authors: B J Lange; N Kobrinsky; D R Barnard; D C Arthur; J D Buckley; W B Howells; S Gold; J Sanders; S Neudorf; F O Smith; W G Woods Journal: Blood Date: 1998-01-15 Impact factor: 22.113
Authors: Gina Mundschau; Sandeep Gurbuxani; Alan S Gamis; Marianne E Greene; Robert J Arceci; John D Crispino Journal: Blood Date: 2003-01-30 Impact factor: 22.113
Authors: Ting Zhou; Peishuai Chen; Jian Gu; Alexander J R Bishop; Linda M Scott; Paul Hasty; Vivienne I Rebel Journal: Int J Mol Sci Date: 2015-01-05 Impact factor: 5.923
Authors: Ruma Raha-Chowdhury; James W Henderson; Animesh Alexander Raha; Simon R W Stott; Romina Vuono; Simona Foscarin; Liam Wilson; Tiina Annus; Robert Fincham; Kieren Allinson; Vinod Devalia; Robert P Friedland; Anthony Holland; Shahid H Zaman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472